L-Carnitine therapy improves right heart dysfunction through Cpt1-dependent fatty acid oxidation

Vineet Agrawal1 | Anna R. Hemnes2 | Nicholas J. Shelburne2 | Niki Fortune2 | Julio L. Fuentes2 | Dan Colvin3 | Marion W. Calcutt4 | Megha Talati2 | Emily Poovey2 | James D. West2 | Evan L. Brittain1

1Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
2Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
3Vanderbilt University Institute of Imaging, Vanderbilt University, Nashville, Tennessee, USA
4Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA

Correspondence
Vineet Agrawal, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Medical Research Bldg IV, Room P475, 2213 Garland Ave, Nashville, TN 37232, USA.
Email: vineet.agrawal@vumc.org

Abstract
Pulmonary arterial hypertension (PAH) is a fatal vasculopathy that ultimately leads to elevated pulmonary pressure and death by right ventricular (RV) failure, which occurs in part due to decreased fatty acid oxidation and cytotoxic lipid accumulation. In this study, we tested the hypothesis that decreased fatty acid oxidation and increased lipid accumulation in the failing RV is driven, in part, by a relative carnitine deficiency. We then tested whether supplementation of L-carnitine can reverse lipotoxic RV failure through augmentation of fatty acid oxidation. In vivo in transgenic mice harboring a human BMPR2 mutation, L-carnitine supplementation reversed RV failure by increasing RV cardiac output, improving RV ejection fraction, and decreasing RV lipid accumulation through increased PPARγ expression and augmented fatty acid oxidation of long chain fatty acids. These findings were confirmed in a second model of pulmonary artery banding-induced RV dysfunction. In vitro, L-carnitine supplementation selectively increased fatty acid oxidation in mitochondria and decreased lipid accumulation through a Cpt1-dependent pathway. L-Carnitine supplementation improves right ventricular contractility in the stressed RV through augmentation of fatty acid oxidation and decreases lipid accumulation. Correction of carnitine deficiency through L-carnitine supplementation in PAH may reverse RV failure.

Keywords
metabolism, pulmonary arterial hypertension, right heart failure
INTRODUCTION

Pulmonary arterial hypertension (PAH) is a progressive, fatal vasculopathy of the pulmonary arteries. Despite current therapies, more than 50% of patients die within 5 years of diagnosis of PAH. The most common cause of death in PAH is right ventricular (RV) failure which has no effective treatment, highlighting the need for therapies that directly improve RV function in PAH. PAH is associated with systemic abnormalities in glucose and lipid metabolism that are thought to result from abnormalities in fatty acid processing, and a consequence of these alterations in metabolism in the PAH RV is a decrease in fatty acid oxidation and concomitant accumulation of lipotoxic metabolites in the failing RV.

To date, there are no effective strategies for reducing lipid accumulation and improving fatty acid oxidation in the diseased RV. While incompletely understood, one mechanism that is thought to contribute to decreased β-oxidation of fatty acids is a deficiency of carnitine in the failing RV. Carnitines are a family of compounds considered indispensable for β-oxidation of fatty acids that are involved in the conjugation of and transport of long chain fatty acids across the mitochondrial membranes, thereby facilitating β-oxidation and adenosine triphosphate (ATP) generation. Multiple studies have now demonstrated an accumulation of long chain fatty acids in the plasma and RV of patients with PAH, perhaps a consequence of decreased fatty acid oxidation. One strategy for improving RV fatty acid oxidation may be through supplementation of L-carnitine to improve conjugation and transport of long chain fatty acids into mitochondria. Carnitine supplementation has not yet been studied in the context of RV failure in PAH, and additionally the mechanisms by which L-carnitine may affect cardiac function are also not well understood.

In this study, we sought to test the hypothesis that L-carnitine supplementation reverses RV dysfunction and increases fatty acid β-oxidation in the diseased RV. We studied the effects of L-carnitine supplementation on the hemodynamic and structural remodeling of the RV as well as fatty acid oxidation capacity in two models of RV failure in a mouse model harboring a clinically relevant mutation in the BMPR2 gene and a model of load stress on the RV imposed by pulmonary artery banding. We further tested the mechanism of carnitine’s effect on cardiomyocytes using cell culture techniques.

METHODS

Patient samples and plasma collection

Patients with idiopathic PAH or heritable PAH followed at the Vanderbilt University Medical Center over a 2-year period, aged ≥18 years and without a known diagnosis of polycystic ovarian syndrome, diabetes mellitus, therapy with an oral hypoglycemic agent or other diabetic therapy were eligible to participate. Plasma was collected from patients who underwent clinically indicated right heart catheterization. Plasma was also collected from age-, sex-, and body mass index-matched healthy volunteers free from cardiovascular disease or diabetes mellitus. After sample collection, plasma was immediately isolated by centrifugation and stored at −80°C for metabolomic analysis as previously described.

Animal studies

Wild type C57BL6/J mice and transgenic mice harboring a disease-causing human mutation in BMPR2 were used for this study. Each group contained roughly equal numbers of female and male mice, and all mice were 10–12 weeks old at the start of the study. For BMPR2 mutant mouse studies, mice were fed a high-fat diet as previously described for 6 weeks to cause RV lipid accumulation as previously described. After 6 weeks, mice were given either control water or water supplemented with 200 mg/kg/day of L-carnitine for 10 weeks. As a second model of right heart strain induced by load stress, wild type C57BL6/J mice underwent sham surgery or pulmonary artery banding with a high-fat diet as previously described. Mice were then treated immediately after surgery with L-carnitine (200 mg/kg/day) or vehicle (water) control in their water for 2 weeks. At the end of the study period, all mice underwent either echocardiography or cardiac magnetic resonance imaging (MRI) (see Supporting Information for detailed methods of cardiac MRI), cardiac catheterization as previously described, isolation of tissue for mitochondrial respiration studies (detailed methods in Supporting Information), and tissue harvest for analysis of RNA, protein, histology, and mass spectrometry for lipid metabolites as previously described. Primer sequences for RT-PCR and antibodies with concentrations used for immunostaining are detailed in the Supporting Information.

Cell studies

The H9C2 rat myoblast cell line was transfected with either a plasmid containing a cytoplasmic mutation in the BMPR2 gene (2579-2580 delT) or empty vector control. To measure lipid accumulation in cells, cells were stained with BODIPY 493/502 stain (Invitrogen) at a concentration of 0.1 μg/ml and counterstained with DAPI stain after fixation in 4% paraformaldehyde. A subset of cells was also assayed for mitochondrial...
respiration using a Seahorse XFe96 Analyzer (see Supporting Information for detailed methods).

**Statistical analysis**

Differences in measurements in animal studies were assessed using one-way analysis of variance with the Tukey post hoc test. A $p < 0.05$ was considered significant. Differences in plasma metabolite levels of free carnitine and long chain acylcarnitines in human samples were assessed using the Mann–Whitney test comparing samples from patients with pulmonary hypertension versus control. A $p < 0.05$ was considered significant.

**RESULTS**

**Long-chain fatty acid to carnitine ratios are increased in patients with pulmonary arterial hypertension**

We first measured free carnitine (C0), medium-chain (C10), and long chain (C18) acylcarnitine levels in the plasma of patients with pulmonary arterial hypertension ($n = 27$) and control patients without pulmonary hypertension ($n = 37$). Compared to controls, the ratio of long chain (C18) to free carnitine levels was increased in PAH patients. Medium-chain (C10) to free carnitine levels were unchanged between groups (Figure 1, Supporting Information: Figure S1). Relative to the circulating levels of long chain fatty acids in patients with PAH, free carnitine levels were not correspondingly elevated (Supporting Information: Figure S1), suggestive of a relative free carnitine deficiency in patients with PAH.

**L-Carnitine supplementation improves systolic of the RV in R899X BMPR2 mutant mice**

We next sought to determine whether supplementation of L-carnitine could improve RV function in a mouse model of PAH harboring a clinically relevant mutation in BMPR2 (R899X). Whereas there were no significant differences in wild type given control or L-carnitine supplementation, L-carnitine in BMPR2 mutant mice led to an increase in measured cardiac output, maximum contractility ($dP/dt$ max), decrease in diastolic relaxation constant $\tau$, and decrease in pulmonary vascular resistance (Figure 2, Supporting Information: Figure S2). When the diastolic relaxation constant, $\tau$, was normalized to resting heart rate, no significant changes were noted (Supporting Information: Figure S3). There were no changes in RV systolic pressure, RV to body weight ratio, or Fulton Index. Magnetic resonance imaging of the hearts of mice also confirmed that R899X mutant mice, but not wild type mice, given L-carnitine supplementation showed an increase in RV ejection fraction, RV cardiac output, and RV stroke volume (Figure 3a, Supporting Information: Table S1). Plasma analysis confirmed that L-carnitine supplementation led to an increase in plasma concentrations of L-carnitine in both wild type and R899X mice (Supporting Information: Figure S4).

**L-Carnitine decreases fatty acid accumulation in the RV of R899X BMPR2 mutant mice and increases acylcarnitines**

We next used Oil Red O in histologic sections to determine whether there was a change in measured fat within the RV of mice R899X mice given L-carnitine. Compared to vehicle control, L-carnitine supplementation led to a 61% decrease in Oil Red O staining on sections (Figure 3b, Supporting Information: Figure S5). Metabolomic analysis by mass spectrometry of lipid contents of the plasma and RV demonstrated that L-carnitine treatment resulted in a 82% decrease in the acylcarnitine to free carnitine ratio in the plasma of R899X mice (Figure 3c). There was a nonsignificant trend towards a decrease in acylcarnitine to free carnitine ratio in the RV of R899X mice that were treated with L-carnitine (Figure 3d).
L-carnitine increases fatty acid mediated mitochondrial respiration and β-oxidation of fatty acids

To assess whether L-carnitine supplementation improved fatty acid-mediated mitochondrial respiration, a subset of mice were killed and the RV tissue was immediately permeabilized for measurement of oxygen respiration in response to various substrates and inhibitors of mitochondrial respiration. All data were normalized to mitochondrial density in the RV by Tom20 stain (Supporting Information: Figure S6). The RVs in R899X mice treated with L-carnitine showed increased respiratory capacity via complex I-mediated respiration (glutamate/malate) (Figure 4a), long chain fatty acid-mediated oxidation (palmitoyl-carnitine) (Figure 4b), and complex II-mediated respiration (succinate) (Figure 4d) compared to controls. There were no differences between R899X and control RVs in response to medium-chain fatty acids (octanoyl-carnitine) as a result of L-carnitine treatment (Figure 4c).

Figure 2
Invasively measured (a) cardiac output, (b) systolic contractility (dP/dt max), (c) diastolic relaxation (τ), (d) RV systolic pressure, (e) RV to body weight ratio, (f) Fulton Index (RV to LV+ septal weight ratio), and (g) pulmonary vascular resistance (PVR) in wild type and R899X mutant mice after 10 weeks of supplementation with L-carnitine. *p < 0.05. **p < 0.01. Error bars represent standard deviation. N = 13–15 for each group. Carn, L-carnitine; LV, left ventricular; RV, right ventricular.
Oxidized lipids are also a natural ligand for peroxisome proliferator-activated receptors (PPAR), a family of nuclear receptors that regulate mitochondrial respiration and metabolism that have been shown to be diminished in the PAH RV. Thus, we next investigated whether metabolic changes in response to 1-carnitine treatment may be, in part, mediated by changes in PPAR expression. Immunostain for PPARα and PPARγ demonstrated an increase in expression of PPARγ in the RV of R899X mice treated with 1-carnitine (Figure 5a). As a result, downstream transcription of regulators of fatty acid oxidation was also increased in R899X mice that received 1-carnitine as opposed to control (Figure 5b).

1-Carnitine decreases lipid accumulation and increases Cpt-1-dependent fatty acid oxidation in vitro

We finally sought to confirm whether the effects of 1-carnitine on fatty acid oxidation were directly attributable to cardiomyocytes through the use of an in vitro model of cardiomyocyte-like cells harboring a BMPR2 mutation or controls. H9C2 cells transfected with either empty vector control or a cytoplasmic domain mutation in the BMPR2 gene were treated with 1-carnitine or loading control in the setting of bovine serum albumin (BSA):Palmitate and subsequently fixed and stained for lipid accumulation. 1-Carnitine improved lipid accumulation and increased Cpt-1-dependent fatty acid oxidation.
FIGURE 4 Mitochondrial respiration and oxygen flux response to (a) glutamate/malate treatment (Complex I), (b) palmitoyl-carnitine (long chain fatty acid), (c) octanoyl-carnitine (medium chain fatty acid), and (d) succinate (Complex II). *p < 0.05. N = 4 per group.

FIGURE 5 (a) Immunostain of the RV for PPARγ and PPARα in wild type and R899X mice with and without L-carnitine supplementation (****p < 0.0001, n = 3 samples for each group). (b) RT-PCR for mRNA transcript expression in wild type and R899X mice with and without L-carnitine supplementation for regulators of fatty acid oxidation ($p < 0.05$ between wild type and R899X mice, #p < 0.05 between R899X mice treated with L-carnitine vs. control) (bar = 50 µm). N = 6 animals per group. mRNA, messenger ribonucleic acid; PPAR, peroxisome proliferator-activated receptors; RT-PCR, real time reverse transcription–polymerase chain reaction; RV, right ventricle.
accumulation in BMPR2-mutant H9C2 cells but had no effect on wild type H9C2 cells (Figure 6a,b). Additionally, BMPR2 mutant and wild type H9C2 cells were analyzed for the ability of their mitochondria to undergo mitochondrial respiration in the presence of palmitate conjugated BSA in vitro. Cells were sequentially treated with Oligomycin, FCCP, and Rotenone/Antimycin A to determine basal respiration, ATP-linked respiration, maximal respiratory capacity, nonmitochondrial respiration, and reserve capacity. In BMPR2 mutant H9C2 cells, there was a decrease in the overall maximal respiratory capacity of fatty acids compared to wild type H9C2 cells, consistent with a decreased ability to undergo fatty acid β-oxidation. With supplementation of 0.5 mM L-carnitine, the overall mitochondrial respiratory capacity of fatty acids was increased by 65% in H9C2 cells harboring the BMPR2 mutation but not wild type H9C2 cells (Figure 6c,d). Treatment with a Cpt1 inhibitor, etoxim, abolished all oxygen consumption in both cell types, confirming that the assay was indeed measuring mitochondrial oxidation of fatty acid oxidation and that L-carnitine's effect is Cpt1-dependent. Taken together, these findings confirm that L-carnitine directly regulates fatty acid oxidation in RV tissue, specifically cardiomyocytes, in a CPT1 dependent manner to improve mitochondrial function.

**L-Carnitine improves right ventricular function and fatty acid oxidation after pulmonary artery banding**

We utilized a second model of RV stress induced by pulmonary banding and high-fat diet in wild type mice to determine if the effects of L-carnitine on RV function were independent of any potential effect on pulmonary vasculature, and to determine if its effect was selective to mice harboring a BMPR2 mutation or more generalizable to RV load stress (Supporting Information: Figure S8). Two weeks after wild type C57/BL6 mice underwent pulmonary artery banding and high-fat diet initiation as metabolic stress, mice were given either L-carnitine supplementation in the water or control for 2 weeks. Mice given L-carnitine supplementation demonstrated increased cardiac output, stroke work, stroke volume, decreased end-arterial elastance (Ea), increased end-systolic elastance (Ees), and overall decreased Ea/Ees ratio compared to control mice that did not receive L-carnitine (Figure 7).
DISCUSSION

The present study investigated whether L-carnitine supplementation could reverse RV lipid accumulation and RV dysfunction in two separate models. We further demonstrated that this occurs through increased fatty acid oxidation, decreased lipid accumulation, and enhancement of PPARγ-mediated transcription of regulators of fatty acid oxidation (Figure 8). The diseased RV in PAH displays diminished PPARγ activity and diminished fatty acid oxidation capacity,22–24 both of which contribute to the accumulation of lipotoxic intermediates in the myocardium.12,17,25 Thus, our findings suggest that L-carnitine treatment may improve lipotoxicity in the diseased RV in part through the restoration of normal levels of fatty acid oxidation. Furthermore, our findings confirming a similar benefit in pulmonary artery-banded wild type mice also suggest that the effect of L-carnitine may be applicable more generally to RV dysfunction that occurs as a result of load stress.

Most studies to date have attempted to target metabolic remodeling in the RV by preferentially decreasing fatty acid oxidation further and increasing glucose oxidation through pyruvate dehydrogenase kinase inhibition.26 While successful in preclinical models, this approach has yielded mixed results in a clinical trial.27 A logical approach toward targeting metabolic remodeling in the RV would be to attempt to restore the normal balance of fatty acid and glucose oxidation.
glucose oxidation for energy generation. Studies of the pressure-loaded left ventricle have indeed demonstrated that preservation of fatty acid oxidation can prevent the pathologic decrease in contractility associated with cardiac hypertrophy.26–30 Therapies such as metformin have been shown to reduce lipid accumulation in preclinical models and triglyceride content in human RVs with PAH,17,31 but whether these changes are driven by fatty acid oxidation-related changes or not is not known.

Although previous studies have suggested that augmentation of fatty acid oxidation通过 genetic means may prevent cardiomyopathy,22,28,29 our study utilized a readily available pharmacologic therapy that is readily translatable to humans and demonstrated that augmentation of fatty acid oxidation can reverse RV failure. This is particularly relevant for two reasons. The first is that features of metabolic dysfunction are disproportionately prevalent in patients with PAH, occurring in patient demographics that would otherwise not be considered “at risk” for development of complications such as insulin resistance, hyperglycemia, and hyperlipidemia.6,12 The second reason is that our therapeutic approach via L-carnitine supplementation is known to be a safe intervention, even at high doses.32 The findings of our study support previous work by our group and others that have demonstrated that PAH is characterized by an acquired state of deficient levels of carnitine,11,13,33,34 which is important for shuttling of fatty acids to the mitochondrial membrane for β-oxidation. The findings of the present study demonstrate that exogenous supplementation of L-carnitine can, at least partially, increase acycarnitine levels in the RV and increase fatty acid oxidation.

An acquired carnitine deficiency has been reported in multiple forms of cardiomyopathies, primarily ischemic and nonischemic left heart failure. In a meta-analysis of small clinical studies investigating the efficacy of L-carnitine supplementation in improving left heart failure, there was a 4% increase in LV ejection fraction and a mild 0.47 cm decrease in end-diastolic diameter, but overall no change was noted in adverse events, mortality, or symptoms.32 One study of patients with PAH showed that intravenous L-carnitine supplementation (5 g/day) for 7 days improved functional markers such as 6-min walk distance and WHO functional class, and simultaneously led to a decrease in measured B-type natriuretic peptide levels (58.16 vs. 33.29 ng/L), supporting the potential benefit of L-carnitine therapy in RV dysfunction as well.35 Whether L-carnitine may itself improve RV function, lipotoxicity, or longer-term outcomes such as heart failure hospitalization, or mortality is not clear. RV failure does not respond to conventional therapies used for medical management of LV failure, and mechanistically metabolic derangement appears to be a more central mechanism that drives RV failure compared to LV failure.36 Carnitine deficiency is less well studied in diseases of the right ventricle, but previous studies from our group and others suggest prominent defects in fatty acid oxidation underlie the development and progression of RV failure in PAH.11,25,37 Most notably, elevated plasma acylcarnitine levels are both associated with both worse RV function and overall worse prognosis in PAH.11,13 Although the mechanisms underlying elevated acylcarnitine levels in PAH are not completely understood, one plausible mechanism may be that acylcarnitines accumulate due to defective transport into mitochondria for fatty acid oxidation.11,13

In our study, exogenous supplementation of L-carnitine decreased the accumulation of cytoplasmic acylcarnitines by directly increasing fatty acid β-oxidation in mitochondria. We saw no effect of L-carnitine upon total mitochondrial density, but our data suggest a selective increase in mitochondrial β-oxidation of long chain fatty acids in response to L-carnitine supplementation in both in vivo and in vitro models through a Cpt1-dependent mechanism. Augmentation of fatty acid oxidation also led to a feed-forward loop through the activation of master metabolic regulator PPARγ and increased transcription of fatty acid oxidation-related genes.

Our study has limitations. Our first model of transgenic mice harboring the BMPR2 mutant gene are incompletely penetrant and in this experiment did not develop elevated pulmonary pressures, as noted in our results. They do, however, recapitulate many cardiac and systemic features that are present in heritable PAH due to BMPR2 mutation, such as lipid accumulation, decreased ejection fraction, and insulin resistance.10–12,17 A number of studies have suggested that the presence of a BMPR2 mutation in heritable PAH is associated with cardiomyopathic changes independent of the load stress imposed by pulmonary vascular remodeling, and thus the BMPR2 mutant mouse model in our study is still applicable to patients with heritable PAH or idiopathic PAH associated with decreases in BMPR2 expression.11,12,38–40 To address the potential effects of load stress and to partially account for limitations of the BMPR2 transgenic mice used in this study, we used a second model of mechanically imposed load stress on the RV in wild type C57/BL6 by pulmonary artery banding to assess effects of L-carnitine supplementation independent of any effect on pulmonary vascular remodeling. Future studies with other models in which pulmonary vascular remodeling occurs (e.g., Sugen-hypoxia or monocrotaline) may further clarify the effect of L-carnitine supplementation on RV dysfunction. A second limitation of our study was that L-carnitine...
supplementation was provided through the drinking water, and thus the exact amount of supplement given to each animal cannot be entirely standardized. While our data show a significant increase in plasma carnitine levels with supplementation, our study did not control for the amount supplemented per mouse. Finally, our study was also limited to an assessment of l-carnitine supplementation’s effect on RV structure and function. We note that l-carnitine supplementation led to a greater decrease in plasma acylcarnitine ratio compared to RV, and thus extra-cardiac effects of l-carnitine supplementation cannot be ruled out. Future studies will be needed to investigate the possibility of interorgan crosstalk as a contributing mechanism to the efficacy of l-carnitine supplementation.

In conclusion, we demonstrate that augmentation of fatty acid oxidation in the PAH RV through supplementation of l-carnitine improves relative carnitine deficiency, increases mitochondrial fatty acid oxidation, and improves RV function.

AUTHOR CONTRIBUTIONS
Vineet Agrawal, Anna R. Hemnes, Nicholas J. Shelburne, Niki Fortune, James D. West, and Evan L. Brittain designed research studies. Vineet Agrawal, Nicholas J. Shelburne, Niki Fortune, Julio L. Fuentes, Dan Colvin, Marion W. Calcutt, Megha Talati, and Emily Poovey conducted experiments and acquired data. Vineet Agrawal, Anna R. Hemnes, Nicholas J. Shelburne, Niki Fortune, James D. West, and Evan L. Brittain analyzed data. Vineet Agrawal, Anna R. Hemnes, and Evan L. Brittain wrote the manuscript.

ACKNOWLEDGMENTS
NIH 5R01HL122417 (A. R. Hemnes), 3R01HL122417-04S1 (A. R. Hemnes), Team Phenomenal Hope Award (V. Agrawal), Pulmonary Hypertension Association Young Investigator Award (V. Agrawal), NIH 1K08HL153956 (V. Agrawal).

CONFLICTS OF INTEREST
V. A., E. L. B., A. R. H., and J. D. W. have all received grants from the NIH/NHLBI. V. A. has received funding from the American Heart Association, Team Phenomenal Hope Foundation, and Pulmonary Hypertension Association. A. R. H. has served as a consultant to Janssen, Complexa, GossamerBio, Bayer, United Therapeutics. A. R. H. has received funding from CMREF. A. R. H. owns stock in Tenax Thera.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT
All human studies were approved by the Vanderbilt University Medical Center Institutional Review Board (protocols 9401, 130712, and 140983). All animal studies were approved by the Vanderbilt University Medical Center Institutional Animal Care and Use Committee (protocol M1800073). All animal studies were approved by the Vanderbilt University Institutional Animal Care and Use Committee (IACUC). The collection of human plasma samples was approved by the Institutional Review Board at Vanderbilt University Medical Center, and all subjects provided written informed consent.

ORCID
Vineet Agrawal http://orcid.org/0000-0002-8457-6722 Nicholas J. Shelburne http://orcid.org/0000-0003-3008-9555

REFERENCES
1. Prins KW, Thenappan T. World Health Organization group I pulmonary hypertension. Cardiol Clin. 2016;34:363–74.
2. Humbert M, Lau EMT, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189–208.
3. Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14:603–14.
4. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122:164–72.
5. Inampudi C, Hemnes AR, Briasoulis A. Approach to a patient with pulmonary hypertension. J Geriatr Cardiol . 2019;16:478–81.
6. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Hear Lung Transplant. 2011;30:904–11.
7. Trammell AW, Talati M, Blackwell TR, Fortune NL, Niswender KD, Fessel JP, Newman JH, West JD, Hemnes AR. Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension. Pulm Circ. 2017;7:624–34.
8. Hemnes AR, Luther JM, Rhodes CJ, Burgess JP, Carlson J, Fan R, Fessel JP, Fortune N, Gerszten RE, Halliday SJ, Hekmat R, Howard L, Newman JH, Niswender KD, Pugh ME, Robbins IM, Sheng Q, Shibao CA, Shyr Y, Sumner S, Talati M, Wharton J, Wilkins MR, Ye F, Yu C, West J, Brittain EL. Human PAH is characterized by a pattern of lipid-related insulin resistance. JCI Insight. 2019;4:e123611. https://doi.org/10.1172/jci.insight.123611
9. Archer SL, Fang YH, Ryan JJ, Piao L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ. 2013;3:144–52
10. Talati MH, Brittain EL, Fessel JP, Penner N, Atkinson J, Funke M, et al. Mechanisms of lipid accumulation in the bone morphogenetic protein receptor type 2 mutant right ventricle. Am J Respir Crit Care Med. 2016;194:719–28.

11. Brittain EL, Talati M, Fessel JP, Zhu H, Penner N, Calcott MW, et al. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. Circulation. 2016;133:1936–44.

12. Hemmes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2014;189:325–34.

13. Luo N, Craig D, Ilkalaya O, Muehlbauer M, Kraus WE, Newgard CB, et al. Plasma acylcarnitines are associated with pulmonary hypertension. Puli Circ. 2017;7:211–18.

14. Longo N, Atam Di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet. 2006;142C:77–85.

15. Hemmes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2014;189:325–34.

16. West J, Niswender KD, Johnson JA, Pugh ME, Gleaves L, Fessel JP, et al. A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J. 2013;41:861–71.

17. Brittain EL, Talati M, Fortune N, Agrawal V, Meoli DF, West J, et al. Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy. Puli Circ. 2019;9:204589401881774.

18. Agrawal V, Fortune N, Yu S, Fuentes J, Shi F, Nichols D, et al. Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. Puli Circ. 2019;9:2045894019878599.

19. Johnson JA, Hemmes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, et al. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am J Physiol-Lung Cell Mol Physiol. 2012;302:474–84. https://doi.org/10.1152/ajplung.00202.2011

20. Grygiel-Górnia B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review. Nutr J. 2014;13:17. https://doi.org/10.1186/1475-2891-13-17

21. Hansmann G, Calvier L, Risbano MG, Chan SY. Activation of the metabolic master regulator PPARY: a potential PIONeering therapy for pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2020;62:143–56

22. Legchenko E, Chouvarine P, Borchert P, Fernandez-Gonzalez A, Snay E, Meier M, et al. PPARY agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018;10:eaa0303. https://doi.org/10.1126/scitranslmed.aao0303

23. Chouvarine P, Giera M, Kastenmüller G, Artati A, Adamski J, Bertham H, et al. Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension. Heart. 2020;106:1332–41. https://doi.org/10.1136/heartjnl-2019-315900
37. Rabinovitch M. PPARγ and the pathobiology of pulmonary arterial hypertension. Adv Exp Med Biol, 661:447–58. doi:10.1007/978-1-60761-500-2_29
38. Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016;4:129–37.
39. van der Bruggen CE, Happe CM, Dorfmüller P, Trip P, Spruit OA, Rol N, et al. Bone morphogenetic protein receptor type 2 mutation in pulmonary arterial Hypertension CLINICAL PERSPECTIVE. Circulation. 2016;133:1747–60.
40. Girerd B, Montani D, Eyries M, Yaici A, Sztrymf B, Coulet F, et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res. 2010;11:73. https://doi.org/10.1186/1465-9921-11-73

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Agrawal V, Hemnes AR, Shelburne NJ, Fortune N, Fuentes JL, Colvin D, Calcutt MW, Talati M, Poovey E, West JD,Brittain EL. L-Carnitine therapy improves right heart dysfunction through Cpt1-dependent fatty acid oxidation. Pulm Circ. 2022;12:e12107. https://doi.org/10.1002/pul2.12107